Nkarta, Inc. Profile Avatar - Palmy Investing

Nkarta, Inc.

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cel…

Biotechnology
US, South San Francisco [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of NKTX's Analysis
CIK: 1787400 CUSIP: 65487U108 ISIN: US65487U1088 LEI: - UEI: -
Secondary Listings
NKTX has no secondary listings inside our databases.